Are there more gains ahead for Inovio Pharmaceuticals (INO)?
Inovio Pharmaceuticals (INO) currently trades at $7.72 and has fallen by 4.93% today. INO went down $0.40 from the previous closing price of $8.12. The high forecast for Inovio Pharmaceuticals is $13.00 and the low is $7.00. The company’s market cap is $1.13 billion with a 52 week high of $19.36 and a 52 week low of $1.92. INO has changed in price by 3.75 per share in the last 12 months. The company, which has developed DNA technology called SynCon and its CELLECTRA electroporation delivery system to stimulate immune responses to target virus-infected or tumor cells, has made significant headway in its COVID-19 vaccine development program. As a result, one analyst believes additional gains are in store on top of its already achieved 145% year-to-date rise.
Inovio Pharmaceuticals has a weak EPS of -1.21. This means the company lost $-1.21 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information written in this article.
About Inovio Pharmaceuticals:
Inovio Pharmaceuticals, Inc. researches and develops pharmaceuticals. The Company develops cancer DNA and infectious DNA vaccines, anti-inflammatory drugs, and animal health products. Inovio Pharmaceuticals serves the healthcare sector in the United States.